Takeda Revises Financial Forecast for FY2025

On October 30, 2025, Takeda Pharmaceutical Company Limited announced a revised forecast for its full-year consolidated financials for FY2025, ending March 31, 2026. The updated forecast reflects changes in revenue and profit expectations due to strategic decisions and market conditions.

The forecasted revenue decreased to JPY 4,500 billion, down 0.7% from the original estimate, largely due to revised expectations for ENTYVIO and a decline in U.S. sales of VYVANSE due to generic competition. Additionally, operating profit is anticipated to decrease by 15.8% to JPY 400 billion, driven by an unfavorable product mix and currency exchange challenges.

Net profit attributable to the company is expected to be JPY 153 billion, a 32.9% decrease from the original forecast, influenced by impairment charges and a higher effective tax rate. Core financial measures also reflect modest declines, with core EPS adjusted from JPY 485 to JPY 479.